Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011)

NCT01553279 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

284

Enrollment

INDUSTRY

Sponsor class

Conditions

Neisseria Meningitidis
Bacterial Infections
Virus Diseases

Interventions

BIOLOGICAL: V419
BIOLOGICAL: PREVNAR 13®
BIOLOGICAL: MCC-TT
BIOLOGICAL: MCC-CRM
BIOLOGICAL: Hib-MCC
BIOLOGICAL: MMR Vaccine

Sponsor

MCM Vaccines B.V.